Long-acting Etonogestrel Microspheres

Product Overview

Development Status: Active Development

Target: Female

Mode: Hormonal

Delivery Type: Injectable, Subdermal

Duration Type: Long-acting

Description: Orbis Biosciences is developing a 6-month injectable microsphere formulation containing etonogestrel using Orbis Biosciences' patented Precision Particle Fabrication (PPF) technology for achieving uniform particle size.

Updated date: October 14, 2016

Vertical Tabs

Status

Project Phase: Early Development

Project Stage: Pre-clinical

Began discovery in: 2013

Download Product Report